University of Geneva spinout ABCDx has raised an undisclosed amount in its first funding round.
ABCDx, a Switzerland-based diagnostic products spinout from University of Geneva, raised an undisclosed amount in seed funding today from Geneva-based private investors.
Founded in 2014, ABCDx is working on blood biomarker technologies that enable faster and more cost-effective decisions about treatment for brain injuries and stroke.
The spinout is initially focusing on enabling early decision-making to ensure patients receive life-saving drugs in time. Longer-term, the spinout hopes to adapt its technology to determine whether a patient is suitable for new…
